IATA, Pharma.Aero Team Up to Improve Association’s CEIV Pharma Program
The organizations conducted an in-depth study of the program over the course of two years, publishing a white paper on the findings.
The International Air Transport Association (IATA) and Pharma.Aero, a platform that helps provide the safe transportation of medicine, cures, and vaccines from manufacturing plants to patients, are partnering up in effort to bolster IATA’s Certification for the Excellence in Pharmaceutical Handling (CEIV Pharma) program, which is known for rewarding the global excellence in the realm of pharmaceutical-product handling.1
This process consisted of a two-year endeavor in which both parties closely examined the aforementioned program, featuring professionals in the air logistics space, pharma manufacturers, and certified entities. In February, the organizations ended up publishing their findings of this comprehensive study in a white paper.2
“ … We commend all our members for their time and dedication to this project. Their contributions were decisive in getting first-hand experiences to accurately assess the CEIV Pharma certification and identify opportunities for enhancement,” noted Trevor Caswell, Pharma.Aero chairman. “Together, as Pharma.Aero, we are driving positive change in pharmaceutical logistics to better serve the needs of patients globally.”
This undertaking identified a number of possibilities for growth within the program, such as:
- Striving to increase visibility of IATA CEIV Pharma within the life science manufacturing field
- Growing the network so that it is more accessible to smaller businesses in underserved markets
- Providing a constant effort to improve the certification process, whether it consists of a checklist of independent t validator qualifications or training modules
“The CEIV Pharma program is a trusted mark of quality and excellence in the handling of pharmaceuticals, with hundreds of companies globally across the supply chain, including airlines, ground handling service providers and freight forwarders, achieving certification. This initiative between Pharma.Aero and IATA underscores the continuous commitment to not just maintain but elevate CEIV Pharma certification,” said Frédéric Léger, IATA’s SVP of commercial products and services. “Extensive dialogue with stakeholders has been instrumental in new identifying opportunities for the program, such as reaching smaller enterprises and better serving underserved markets as well as process enhancements.”
References
1. Pharma.Aero and IATA Collaborate to Strengthen IATA CEIV Pharma Program. IATA. News release. March 13, 2024. Accessed March 25, 2024. https://www.iata.org/en/pressroom/2024-releases/2024-03-13-01/
2. CEIV 2.0 Project. Pharma.Aero, IATA. PDF. February 2024. Accessed March 25, 2024. https://pharma.aero/wp-content/uploads/2024/02/CEIV-2.0-Phase-2-Project-White-Paper.pdf
An Exploration of Compounding Practices
May 22nd 2025In a Q&A with Pharma Commerce, Kurt Lunkwitz, ProRx Pharma’s COO, uncovers the stringent requirements that 503B outsourcing facilities must abide by under the Drug Quality and Security Act, while also shedding light on the FDA’s impact when it comes to improving the safety, quality, and trust in compounded drugs.
